Ibex Medical Analytics, a cancer diagnostics provider, demonstrated the positive impact of its AI-powered cancer diagnostic platform Galen on diagnostic quality and efficiency of breast, prostate, and gastric cancers.
The results are from multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham and Women’s Hospital, Champalimaud Foundation, and Ohio State University (OSU). Ibex says these studies will be presented next week at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting.
Ibex’s Galen platform aims to help labs overcome the challenges of increasing demand and diagnostic workloads for cancer diagnostics with AI-powered workflows and decision-support tools that pathologists use in their everyday practice, according to the company.
Study Details of Ibex’s Galen Platform
A study conducted at Brigham and Women’s Hospital and Champalimaud Foundation evaluated Galen Breast’s performance in identifying microinvasive carcinoma of the breast in a challenging patient cohort. Microinvasive carcinoma is defined as the focus of invasive breast cancer no larger than 1mm, in which accurate detection has important implications for patient management. The results indicate that Galen Breast’s AI algorithm is highly accurate in detecting microinvasive lesions and has the potential to improve consistency in diagnosis and support more efficient workflows in pathology laboratories, the company says.
“Microinvasive carcinoma is challenging and time-consuming to identify, and is often subject to overdiagnosis and underdiagnosis, adversely affecting treatment decisions. Therefore, Galen Breast’s accuracy in detecting and classifying these minute tumors is a vital step forward in enhancing diagnostic confidence and providing oncologists with a comprehensive pathology diagnosis,” says Stuart Schnitt, MD, chief of breast oncologic pathology at the Dana-Farber/Brigham Cancer Center, and an investigator in the study.
In another study conducted at UPMC, researchers assessed Galen Prostate’s performance in primary diagnosis of prostate biopsies. The study found the AI-powered solution was highly accurate in identifying and grading cancer in a live clinical setting, with NPV and PPV of 0.991. The study also demonstrated positive feedback from participating pathologists, showing high satisfaction, particularly with Galen Prostate’s Gleason scoring, detection of perineural invasion and automated measurement of tissue and tumor length.
Further reading: Ibex and PathPresenter Partner to Advance AI-powered Digital Pathology Solutions
In addition, researchers from OSU Wexner Medical Center will present studies validating Galen Breast’s performance in detecting different types of breast cancer. This includes invasive and in situ carcinoma, as well as other clinically important pathologies, such as lobular neoplasia and microcalcifications across a diverse cohort of breast biopsies. They will also present a study validating the performance of Galen Gastric in the diagnosis of gastric cancer, neuroendocrine tumors, H.pylori, and other gastric lesions, such as adenoma and low-grade dysplasia.
“Galen offers an unparalleled breadth of detection capabilities going well beyond cancer and becoming an integral part of everyday clinical practice in laboratories, hospitals and health systems globally,” says Chaim Linhart, PhD, chief technology officer and co-founder of Ibex Medical Analytics. “With these outstanding outcomes achieved in leading US healthcare institutions across various tissue types, amplified by very positive user feedback, our technology continues to set the standard for AI solutions in pathology, helping clinicians improve patient outcomes.”
Photo: Ibex
